Cogent Biosciences Inc reports results for the quarter ended in March - Earnings Summary

Cogent Biosciences

09/05/2023 14:31

* Cogent Biosciences Inc  COGT.OQ  reported a quarterly
adjusted
loss of 54 cents​​ per share for the quarter ended in March. The
mean expectation of eight analysts for the quarter was for a
loss of 57 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cogent Biosciences Inc's reported EPS for the quarter was
a loss
of 54 cents​.
    * The mean earnings estimate of analysts had fallen by
about 11.1%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Cogent Biosciences Inc shares had risen by 9.7% this
quarter and
gained 2.4% so far this year.
    * The company reported a quarterly loss of $38.59 million.
    * Wall Street's median 12-month price target for Cogent
Biosciences Inc is $21.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.57          -0.54          Beat
 Dec. 31 2022      -0.52          -0.56          Missed
 Sep. 30 2022      -0.51          -0.50          Beat
 Jun. 30 2022      -0.65          -0.71          Missed